{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Frio-bravo-qweek.simplecast.com%2Fepisodes%2Fepisode-209-do-not-do-LfWCE7R6","width":444,"version":"1.0","type":"rich","title":"Episode 209: Do not Do","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/e7f25359-702b-47e8-97f2-d7f32a376648/89b65036-b2fa-4527-9fd4-f80317fd5fc8/rio_bravo_qweek_podcastlogonew.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/365e24c8-49f6-4cda-9df1-86cc56739ca6\" height=\"200\" width=\"100%\" title=\"Episode 209: Do not Do\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Episode 209: Do not Do \n\nStephanie Granat (medical student) explains three screenings that are USPSTF Grade D (Do not do): Prostate cancer, genital herpes, and pancreatic cancer. Dr. Arreaza shares some insight about testing patients with lower urinary tract symptoms and genital lesions.  \n\nWritten by Stephanie Granat, MSIV, Ross University School of Medicine. Edits and comments by Hector Arreaza, MD.\n"}